Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share (the "Shares")
-
Shares outstanding
-
21,303,054
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
8,915,770
-
Shares change
-
+228,514
-
Total reported value, excl. options
-
$120,541,916
-
Value change
-
+$8,913,830
-
Number of buys
-
29
-
Number of sells
-
-12
-
Price
-
$13.52
Significant Holders of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD) as of Q2 2025
44 filings reported holding AARD - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") as of Q2 2025.
Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8,915,770 shares
of 21,303,054 outstanding shares and own 42% of the company stock.
Largest 10 shareholders include Decheng Capital LLC (3,917,299 shares), CITADEL ADVISORS LLC (1,283,732 shares), Laurion Capital Management LP (989,068 shares), Cormorant Asset Management, LP (800,189 shares), VANGUARD GROUP INC (460,977 shares), SILVERARC CAPITAL MANAGEMENT, LLC (286,807 shares), Schonfeld Strategic Advisors LLC (279,258 shares), BlackRock, Inc. (205,795 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (175,000 shares), and GEODE CAPITAL MANAGEMENT, LLC (136,927 shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.